In Brief: Reprogenesis
This article was originally published in The Gray Sheet
Executive Summary
Reprogenesis: Signs agreement with the University of Massachusetts Medical Center, Worcester, to develop laboratory grown human tissue and "explore its potential uses in surgical procedures ranging from breast reconstruction to orthopedic surgery." Under terms of the agreement, Reprogenesis will have the exclusive rights to develop, manufacture and sell the tissue culture technology...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.